Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832406 | 0.89 | TAAR1 (0.50) | TAAR1ALDH1A1CYP2D6L3MBTL1NPC1 | |
| SCHEMBL15547796 | 0.89 | TAAR1 (0.58) | TAAR1ALDH1A1CYP2D6L3MBTL1HTR2A | |
| SCHEMBL29528231 | 0.89 | TAAR1 (0.62) | TAAR1HTR2AHTR2C | |
| SCHEMBL1048335 | 0.89 | TAAR1 (0.62) | TAAR1HTR2AHTR2C | |
| Ammonia Solution, Strong SCHEMBL27205013 | 0.87 | TAAR1 (0.60) | TAAR1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL31069418 | 0.87 | TAAR1 (0.60) | TAAR1HTR2AHTR2C | |
| SCHEMBL27700248 | 0.86 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| Methane SCHEMBL25287143 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL4668525 | 0.83 | HTR2A (0.48) | ALDH1A1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18995456 | 0.83 | ALDH1A1 (0.54) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129790-B2 | Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates | NORTHEASTERN UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| US-20180369131-A1 | Chemo-Enzymatic Site-Specific Modification of Peptides and Proteins to Form Cleavable Conjugates | NORTHEASTERN UNIVERSITY | 2018-12-27 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-2094670-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369131-A1 | Chemo-Enzymatic Site-Specific Modification of Peptides and Proteins to Form Cleavable Conjugates | GLUL, QPCT, DNPEP | TAAR1 3199/4885ALDH1A1 3701/4885CYP2D6 2520/4885 |
| US-11129790-B2 | Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates | GLUL, QPCT, DNPEP | TAAR1 3199/4885ALDH1A1 3701/4885CYP2D6 2520/4885 |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | TAAR1 4442/4885ALDH1A1 1056/4885CYP2D6 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.